As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer. Its portfolio features CyPath lung, a specialized diagnostic test designed for the early identification of lung cancer. Beyond diagnostics, the firm actively explores targeted therapies intended to combat cancer at a cellular level. This San Antonio, Texas-based company commenced operations in 2014.
| Price | $10.16 |
|---|---|
| Market cap | $4.26M |
| Sector | Healthcare |
| Industry | Medical - Diagnostics & Research |
| Exchange | NASDAQ |
| 52-week range | 4.56-109.35 |
| Beta | -1.12 |
Explore BIAF's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.